stockrow
Friday 6 November 2026
Export NPCE’s income statement to Excel — free account
NeuroPace, Inc.
NPCE Healthcare Medical Devices
NeuroPace, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.0 million, up 25.1% from fiscal 2024.
- Revenue
- −2.95%
- EPS
- +30.8%
- Free cash flow
- −78.7%
- Total debt
- +0.68%
Quarter to June 2026, against a year earlier
12.48
0.21
−1.65%
Follow NPCE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 37 | 41 | 45 | 46 | 65 | 80 | 100 | 99 | +18.0% | 100 | 123 | 152 | +14.9% | |
| Gross margin, % | — | — | — | 71.58 | 73.59 | 74.00 | 71.38 | 73.56 | 73.94 | 77.23 | 81.57 | +5.6 pt | ||||||
| EBT | — | — | — | (30) | (24) | (36) | (47) | (33) | (27) | (21) | (18) | (5.4%) | ||||||
| EBT margin, % | — | — | — | (81.07) | (59.02) | (79.85) | (103.43) | (50.38) | (33.97) | (21.47) | (17.96) | +59.6 pt | ||||||
| Net income | — | 0 | — | (30) | (24) | (36) | (47) | (33) | (27) | (21) | (19) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 183.12 | 200.67 | 2.72 | 1.85 | 2.53 | 2.74 | 3.06 | 2.90 | (49.4%) | |||||
| Earnings | — | — | — | (148.44) | (118.43) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) | (0.57) | (59.4%) | ||||||
| Cash flow | — | — | — | (123.95) | (105.41) | (1.48) | (1.50) | (0.76) | (0.62) | (0.34) | (0.33) | (62.7%) | ||||||
| Capex | — | — | — | (2.30) | (0.30) | (0.02) | (0.02) | (0.01) | (0.01) | (0.01) | (0.01) | (59.5%) | ||||||
| Free cash flow | — | — | — | (126.25) | (105.71) | (1.50) | (1.52) | (0.77) | (0.63) | (0.35) | (0.34) | (62.6%) | ||||||
| Book value | — | — | — | (640.66) | (721.13) | 4.43 | 1.41 | 0.80 | 0.28 | 0.58 | 0.35 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 17 | 25 | 26 | 29 | 33 | 33 | +133.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.16 | 0.16 | 3.71 | 0.78 | 3.86 | 4.08 | 5.05 | 4.35 | 2.5 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 2.28 | 1.02 | 12.24 | 40.67 | 26.55 | 36.22 | 11.8 | ||||||
| EV/Sales | — | — | — | 0.69 | 0.69 | 2.33 | 0.32 | 3.77 | 4.21 | 5.07 | 4.47 | 2.4 | ||||||
| EV/FCF | — | — | — | (1.39) | (1.39) | (4.22) | (0.39) | (12.42) | (18.42) | (44.69) | (38.01) | (11.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (25) | (22) | (25) | (37) | (20) | (18) | (11) | (11) | (12.8%) | |||||
| Capex | — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 | (5.4%) | ||||||
| Free cash flow | — | — | — | (25) | (22) | (25) | (37) | (20) | (18) | (11) | (12) | (12.6%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (55) | 45 | 124 | 87 | 76 | 66 | 76 | 69 | n/m | |||||
| Net debt | — | — | — | 39 | 15 | (66) | (24) | (9) | 7 | (2) | 7 | n/m | ||||||
| Shareholders’ equity | — | — | — | (129) | (148) | 74 | 35 | 21 | 8 | 19 | 12 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (284.17) | (63.02) | (38.08) | (38.02) | (29.72) | (26.83) | (21.44) | (18.82) | +262.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (191.03) | (247.99) | (152.27) | (91.62) | (60.58) | (44.64) | (60.6) pt | ||||||
| ROE | — | — | — | 21.63 | 17.52 | 97.08 | (86.96) | (118.91) | (189.35) | (158.74) | (122.05) | (180.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 152 | 166 | 167 | 171 | 184 | 209 | — | +6.6% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.27 | 0.27 | 0.27 | 0.38 | 0.43 | 0.48 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
NeuroPace, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $502.8M | 1,455× | — (loss-making) | +20.60% (above 0%: growing) | −12.50% (below 0%: shrinking) | −24.45% (below 0%: shrinking) | 89.75% | 8.22% | Compare |
| NPCE NeuroPace, Inc. | $435.6M | — (loss-making) | — (loss-making) | −2.95% (below 0%: shrinking) | n/m | −78.70% (below 0%: shrinking) | 82.83% | (22.53%) | |
| CERS Cerus Corporation | $430.2M | — (loss-making) | — (loss-making) | +6.28% (above 0%: growing) | n/m | +2,471.28% (above 0%: growing) | 57.12% | 0.60% | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $427.1M | 21.2× | — (loss-making) | +35.43% (above 0%: growing) | +40.00% (above 0%: growing) | −51.68% (below 0%: shrinking) | 74.62% | 13.98% | Compare |
| SI Shoulder Innovations, Inc. | $424.1M | — (loss-making) | — (loss-making) | +37.73% (above 0%: growing) | n/m | +38.63% (above 0%: growing) | 78.47% | (46.92%) | Compare |
| SENS Senseonics Holdings, Inc. | $422.5M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| MASS 908 Devices Inc. | $419.5M | — (loss-making) | — (loss-making) | +23.31% (above 0%: growing) | n/m | +150.95% (above 0%: growing) | 51.90% | (79.69%) | Compare |
| RCEL Avita Medical Inc. | $389.5M | — (loss-making) | — (loss-making) | +53.05% (above 0%: growing) | n/m | +86.66% (above 0%: growing) | 84.02% | (17.95%) | Compare |
| SSII SS Innovations International, Inc. | $380.9M | — (loss-making) | — (loss-making) | +39.39% (above 0%: growing) | n/m | −16.62% (below 0%: shrinking) | 50.94% | (16.29%) | Compare |
| Median of peers | $423.3M | — | — | +36.58% | — | +11.01% | 66.86% | (17.12%) |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
19.20%
Entities Affiliated with Accelmed Partners II LP
13.10%
Uri Geiger
13.10%
Entities Affiliated with Soleus Private Equity Fund I, L.P.
8.70%
Polar Capital Partners
8.50%
Morgan Stanley
7.30%
Entities Affiliated with OrbiMed Private Investments VI, LP
7.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement